BOSTON, May 30, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers,...
PYX-201 Phase 1 trial clinical readout on track for fall of 2024 Executive Leadership Team expanded with the appointment of Stephen Worsley as Senior Vice President, Chief Business Officer PYX-106...
BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers,...
BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers,...
Non-dilutive funding to support development of first-in-concept lead Antibody-Drug Conjugate (ADC) asset, PYX-201 Pyxis Oncology retains rights to three other antibodies in development by Apexigen's...
PYX-201 Phase 1 Part 1 trial progressing with initial data expected in the fall of 2024 PYX-106 Phase 1 trial progressing with initial data expected 2H 2024 Completed $50 million private...
Pyxis Oncology Expands Board of Directors
Pyxis Oncology to Present at Leerink Global Biopharma Conference 2024
Pyxis Oncology to Present New PYX-201, PYX-106 and PYX-102 Preclinical Data
BOSTON, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: œPYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat...